Business Context and Reporting Period
This Form 8-K is a current report filed by Inmune Bio, Inc. on August 2, 2023, covering events occurring on August 1, 2023. The company is an emerging growth company incorporated in Nevada, with its principal executive offices in Boca Raton, Florida. Its common stock trades on The NASDAQ Stock Market LLC under the symbol INMB.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is an informational filing regarding a corporate event and does not contain financial statements or performance data.
Material Changes
No material financial changes or operational updates were reported in this filing. The document solely announces a scheduled corporate presentation.
Guidance, Outlook, and Management Commentary
Upcoming Event: On August 1, 2023, the company announced that RJ Tesi, M.D. (Chief Executive Officer) and David Moss (Chief Financial Officer) will present a corporate overview at the BTIG Virtual Biotechnology Conference.
- Date: August 7–8, 2023
- Format: Virtual presentation
- Content: Corporate overview
The filing does not contain specific forward-looking guidance, risk factors, or contingencies beyond the standard disclosure of the upcoming conference.
Investor Verification Checklist
- Verify the date and time of the BTIG Virtual Biotechnology Conference presentation (August 7–8, 2023).
- Confirm the attendance of CEO RJ Tesi and CFO David Moss.
- Review the attached press release (Exhibit 99.1) for any additional details on the presentation agenda.
- Note that this filing contains no new financial data; refer to the most recent 10-Q or 10-K for financial metrics.